Oramed Pharmaceuticals Inc. (ORMP) News
Filter ORMP News Items
ORMP News Results
|Loading, please wait...|
Latest ORMP News From Around the Web
Below are the latest news stories about ORAMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORMP as an investment opportunity.
Oramed Pharmaceuticals Issues Shareholder Update
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value.
ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals’ (NASDAQ:ORMP) recently released top-line results from its ORA-D-013-1 Phase 3 study comparing the efficacy of ORMD-0801 to placebo in patients with T2D (type 2 diabetes) at 26 weeks failed to meet primary and secondary endpoints. Oramed expects to discontinue its oral insulin clinical activities for T2D. This
Wall Street Divided After Key Inflation Reading
Stocks are a mixed bag midday, despite this morning's encouraging consumer price index (CPI).
AVCT Stock Falls as American Virtual Cloud Technologies Files for Bankruptcy
American Virtual Cloud Technologies (AVCT) stock is taking a beating on Thursday as the company, and two subsidiaries, file for bankruptcy.
Why Is Oramed (ORMP) Stock Down 75% Today?
Oramed (ORMP) stock is falling hard Thursday after announcing a Phase 3 clinical trial of its diabetes treatment missed its primary endpoint.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results
Shares of Oramed Pharmaceuticals lost three-quarters of their value, hitting a multi-year low, after the clinical-stage pharmaceutical company said it was throwing in the towel on its most advanced program. + Oramed late Wednesday said its lead product candidate, the oral insulin drug ORMD-0801, missed the primary and secondary endpoints in a Phase 3 study in patients with type-2 diabetes, and that it would share its plans for the drug once full study data is available. + In a filing Thursday wi
Why Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
Oramed’s oral insulin pill fails; stock is down 72%
MARKET PULSE Shares of Oramed Pharmaceuticals Inc. (ORMP) plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial.
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from